Australia, 19th Jun 2025, – Neuralia TMS, a recognised provider of evidence-based neuromodulation therapies in Western Australia, has announced the expansion of its advanced treatment services at its clinic located at 1/273 Railway Avenue, Armadale. The move marks a significant step in broadening access to non-invasive, clinically supported therapies for individuals living with depression, anxiety, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), chronic pain, and Parkinson’s disease.
The clinic’s expanded capabilities include enhanced availability of Transcranial Magnetic Stimulation (TMS), a non-invasive technique that uses magnetic fields to stimulate nerve cells in the brain. TMS has been recognised as a clinically supported treatment option for individuals who have not responded to conventional therapies. Alongside TMS, the clinic is increasing the provision of transcranial Direct Current Stimulation (tDCS), a home-based treatment approach using low-level electrical currents, and pharmacogenetic testing designed to assist clinicians in tailoring interventions based on a patient’s genetic profile.
This expansion is a response to increasing community demand for alternative mental health and neurological therapies. With mental health conditions affecting an estimated one in five Australians each year, the availability of drug-free, neuromodulation-based therapies is being seen as a complementary addition to existing treatment options.
“Expanding access to scientifically supported, non-invasive therapies is central to ensuring that more people receive care tailored to their individual needs,” said a spokesperson for Neuralia TMS. “This development not only reflects growing demand but also a commitment to making clinically validated brain stimulation therapies more accessible across Western Australia.”
Neuralia TMS’s facility in Armadale will continue to offer its full range of services, with increased clinical capacity and additional staff trained in neuromodulation protocols. The expansion also includes upgraded equipment and scheduling systems to improve appointment availability and treatment continuity.
The introduction of enhanced services in the Armadale location aims to reduce barriers for individuals in Perth’s southern suburbs who previously had to travel further distances to receive neuromodulation treatment. By situating advanced therapeutic options within a community-based setting, the clinic is aligning its service model with an evolving healthcare landscape that favours personalised and decentralised care.
Alongside clinical services, Neuralia TMS continues to place emphasis on research-backed practices and patient education. The clinic collaborates with referring healthcare providers, ensuring patients receive integrated care supported by current scientific evidence.
In addition to TMS and tDCS, pharmacogenetic testing is now being offered as part of standard consultations for appropriate patients. This testing involves analysing how an individual’s genetic makeup can influence their response to medications, offering potential improvements in prescribing accuracy for mental health treatments.
The decision to expand follows a sustained period of patient interest and increased referrals from general practitioners and mental health specialists. Industry observers have noted a steady rise in the utilisation of brain stimulation therapies across both urban and regional Australia, driven in part by public awareness and shifts in clinical guidelines supporting non-invasive interventions.
“Neuroscience-based treatments are entering a new era of integration into mainstream mental health care,” the Neuralia TMS spokesperson added. “Looking ahead, the goal remains clear: to continue investing in service expansion, practitioner training, and technology, ensuring that more Australians can access safe and scientifically supported therapies closer to home.”
The clinic continues to operate under strict clinical governance and adheres to all regulatory and ethical standards required for the delivery of neuromodulation services. It is expected that the expanded services in Armadale will become fully operational by mid-June 2025.
For more information about TMS Armadale services, contact Neuralia TMS at 08 6230 3996 or email info@neuraliatms.com.au.
Media Contact
Organization: Neuralia TMS
Contact
Person: Dr Shanek Wick
Website:
https://www.neuraliatms.com.au/
Email:
info@neuralia.com.au
Contact Number: 61391225246
Country:Australia
The post
Neuralia TMS Expands Advanced Therapy Services in Armadale, WA appeared first on
Brand News 24.
It is provided by a third-party content
provider. Brand News 24 makes no
warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Daily Scotland News journalist was involved in the writing and production of this article.